Social Europe

  • EU Forward Project
  • YouTube
  • Podcast
  • Books
  • Newsletter
  • Membership

Covid-19 in India—profits before people

Jayati Ghosh 27th April 2021

Jayati Ghosh explains why more than a third of a million Covid-19 cases are being reported in India daily—and what that says about our world.

Covid-19 India
Jayati Ghosh

The unfolding pandemic horror in India has many causes. These include the complacency, inaction and irresponsibility of government leaders, even when it was evident for several months that a fresh wave of infections of new mutant variants threatened the population. Continued massive election rallies, many addressed by the prime minister, Narendra Modi, brought large numbers to congested gatherings and lulled many into underplaying the threat of infection.

The incomprehensible decision to allow a major Hindu religious festival—the Mahakumbh Mela, held every 12 years—to be brought forward by a full year, on the advice of some astrologers, brought millions from across India to one small area along the Ganges River and contributed to ‘super-spreading’ the disease. Unbelievably, the last major ‘ritual bathing’ goes ahead today!

The exponential explosion of Covid-19 cases—and it is likely much worse than officially reported, because of inadequate testing and undercounting of cases and deaths—has revealed not just official hubris and incompetence but lack of planning and major deficiencies in the public health system. The shortage of medical oxygen, for instance, has effectively become a proximate cause of death for many patients.

Failing vaccination programme

But one significant—and entirely avoidable—reason for the catastrophe is the failing vaccination programme. Even given the global constraints posed by rich-country vaccine-grabbing and the limits on domestic production set by the TRIPS (Trade-Related Aspects of Intellectual Property Rights) agreement, this is unnecessary and unexpected.

India is home to the largest vaccine producer in the world and has several other companies capable of producing vaccines. Before the pandemic, 60 per cent of the vaccines used in the developing world for child immunisation were manufactured in India.

The country has a long tradition of successful vaccination campaigns, against polio and tuberculosis for infants and a range of other diseases. The available infrastructure for inoculation, urban and rural, could have been quickly mobilised.



Don't miss out on cutting-edge thinking.


Join tens of thousands of informed readers and stay ahead with our insightful content. It's free.



In January, the government approved two candidates for domestic use: the Covishield (Oxford-AstraZeneca) vaccine, produced in India by the Serum Institute of India, and Covaxin, produced by Bharat Biotech under a manufacturing licence from the Indian Council of Medical Research (ICMR)—other producers could have been similarly licenced to enhance supply.

The vaccination programme officially started on January 16th, with the initial target of covering 30 million healthcare and frontline workers by the end of March and 250 million people by July. By April 17th, however, only 37 per cent of frontline workers had received both doses (of either vaccine); an additional 30 per cent had received only the first.

Low uptake even among this vulnerable group could have resulted from concerns about the rapid regulatory approval granted to Covaxin, which had not completed Phase III trials. The Indian government also encouraged exports, partly to fulfil commitments by the Serum Institute of India to AstraZeneca and the global COVAX facility—partly to enhance its own standing among developing countries.

But very quickly thereafter, as vaccinations were extended to the over-60s and then those over 45, the shortage was felt and the pace slowed accordingly. By April 24th, only 8.5 per cent of the population had received even one dose—nowhere near what would be required to contain the spread. Even this limited coverage reflected the fact that private facilities had been allowed to administer the vaccine, at a charge of 250 rupees (around €2.76) per dose.

Unrealistic call

The Modi government had obviously made the unrealistic call that that existing domestic production of vaccines would be adequate. In fact, it would have taken the two producers on their own three years to meet the required demand. While the ban on exports of some essential ingredients by the Unites States is affecting production of the AstraZeneca vaccine, Bharat Biotech is constrained by its own finite capacity.

Shockingly, the government did not issue compulsory licences to other producers to increase supply, even though Covaxin had been developed by the public ICMR. It had also allowed several public-sector manufacturing units to languish without adequate investment.

Only on April 16th, after the pandemic had reached crisis proportions across India and showed no signs of abatement, did the central government finally move to allow three public enterprises to make the vaccine—though three other public-run units, with greater expertise and capacity, were inexplicably left out. Even these new units will now need several months to gear up for production.

In the interim, in a uniquely cynical strategy, the Modi government has passed the buck on vaccination to the states, without providing any funding—indeed making them pay higher prices. It has agreed with the private producers a pricing system whereby state governments already desperately short of finances and facing hard budget constraints will have to pay up to four times what the central government pays for the same vaccines. They are now also being allowed to import vaccines from abroad—they will have to bid on their own for that. To create such a Hunger Games among state governments, without central funding and procurement of vaccines for every resident, can only have disastrous outcomes.

Disaster capitalism

The latest sign of this active encouragement of disaster capitalism by the Indian state is even more egregious. In the proposed opening up of vaccination to the 18-45 age group from May 1st, access is to be limited to private hospitals and clinics, and only on payment—with prices ranging from ₹1,200 to ₹2,400 (€13.25-€26.5) per dose! Obviously, the poor will be unable to afford the vaccines, and so the pandemic will rage on, the massive human suffering will continue and countless lives will be lost.

If a novel had been written along these lines, it would be dismissed as too unrealistic and improbable to be taken seriously. Unfortunately, it is only too true—and the strategy of the Indian government is just an extreme example of the privileging of corporate profits over human lives which marks our still-neoliberal world.

This article is a joint publication by Social Europe and IPS-Journal

Jayati Ghosh
Jayati Ghosh

Jayati Ghosh, professor of economics at the University of Massachusetts Amherst, is a member of the Club of Rome’s Transformational Economics Commission and co-chair of the Independent Commission for the Reform of International Corporate Taxation.

Harvard University Press Advertisement

Social Europe Ad - Promoting European social policies

We need your help.

Support Social Europe for less than €5 per month and help keep our content freely accessible to everyone. Your support empowers independent publishing and drives the conversations that matter. Thank you very much!

Social Europe Membership

Click here to become a member

Most Recent Articles

u421983467e464b43d2 1 Why European Security and Sovereignty Depend on Its Digital SectorMariana Mazzucato
u42198346c3fba71fa474 0 As Temperatures Rise, European Workers Face a Looming ThreatMarouane Laabbas-el-Guennouni
u42198346741 4727 89fd 94e15c3ad1d4 3 Europe Must Prepare for Security Without AmericaAlmut Möller
6ybe7j6ybe Why Real Democracy Needs Conflict, Not ConsensusJustus Seuferle
u4219837 46fc 46e5 a3c1 4f548d13b084 2 Europe’s Bid for Autonomy: The Euro’s Evolving Global RoleGuido Montani

Most Popular Articles

u4219834647f 0894ae7ca865 3 Europe’s Businesses Face a Quiet Takeover as US Investors CapitaliseTej Gonza and Timothée Duverger
u4219834674930082ba55 0 Portugal’s Political Earthquake: Centrist Grip Crumbles, Right AscendsEmanuel Ferreira
u421983467e58be8 81f2 4326 80f2 d452cfe9031e 1 “The Universities Are the Enemy”: Why Europe Must Act NowBartosz Rydliński
u42198346761805ea24 2 Trump’s ‘Golden Era’ Fades as European Allies Face Harsh New RealityFerenc Németh and Peter Kreko
startupsgovernment e1744799195663 Governments Are Not StartupsMariana Mazzucato
u421986cbef 2549 4e0c b6c4 b5bb01362b52 0 American SuicideJoschka Fischer
u42198346769d6584 1580 41fe 8c7d 3b9398aa5ec5 1 Why Trump Keeps Winning: The Truth No One AdmitsBo Rothstein
u421983467 a350a084 b098 4970 9834 739dc11b73a5 1 America Is About to Become the Next BrexitJ Bradford DeLong
u4219834676ba1b3a2 b4e1 4c79 960b 6770c60533fa 1 The End of the ‘West’ and Europe’s FutureGuillaume Duval
u421983462e c2ec 4dd2 90a4 b9cfb6856465 1 The Transatlantic Alliance Is Dying—What Comes Next for Europe?Frank Hoffer

ETUI advertisement

HESA Magazine Cover

With a comprehensive set of relevant indicators, presented in 85 graphs and tables, the 2025 Benchmarking Working Europe report examines how EU policies can reconcile economic, social and environmental goals to ensure long-term competitiveness. Considered a key reference, this publication is an invaluable resource for supporting European social dialogue.

DOWNLOAD HERE

Eurofound advertisement

Ageing workforce
The evolution of working conditions in Europe

This episode of Eurofound Talks examines the evolving landscape of European working conditions, situated at the nexus of profound technological transformation.

Mary McCaughey speaks with Barbara Gerstenberger, Eurofound's Head of Unit for Working Life, who leverages insights from the 35-year history of the European Working Conditions Survey (EWCS).

Listen to the episode for free. Also make sure to subscribe to Eurofound Talks so you don’t miss an episode!

LISTEN NOW

Foundation for European Progressive Studies Advertisement

Spring Issues

The Spring issue of The Progressive Post is out!


Since President Trump’s inauguration, the US – hitherto the cornerstone of Western security – is destabilising the world order it helped to build. The US security umbrella is apparently closing on Europe, Ukraine finds itself less and less protected, and the traditional defender of free trade is now shutting the door to foreign goods, sending stock markets on a rollercoaster. How will the European Union respond to this dramatic landscape change? .


Among this issue’s highlights, we discuss European defence strategies, assess how the US president's recent announcements will impact international trade and explore the risks  and opportunities that algorithms pose for workers.


READ THE MAGAZINE

Hans Böckler Stiftung Advertisement

WSI Report

WSI Minimum Wage Report 2025

The trend towards significant nominal minimum wage increases is continuing this year. In view of falling inflation rates, this translates into a sizeable increase in purchasing power for minimum wage earners in most European countries. The background to this is the implementation of the European Minimum Wage Directive, which has led to a reorientation of minimum wage policy in many countries and is thus boosting the dynamics of minimum wages. Most EU countries are now following the reference values for adequate minimum wages enshrined in the directive, which are 60% of the median wage or 50 % of the average wage. However, for Germany, a structural increase is still necessary to make progress towards an adequate minimum wage.

DOWNLOAD HERE

S&D Group in the European Parliament advertisement

Cohesion Policy

S&D Position Paper on Cohesion Policy post-2027: a resilient future for European territorial equity

Cohesion Policy aims to promote harmonious development and reduce economic, social and territorial disparities between the regions of the Union, and the backwardness of the least favoured regions with a particular focus on rural areas, areas affected by industrial transition and regions suffering from severe and permanent natural or demographic handicaps, such as outermost regions, regions with very low population density, islands, cross-border and mountain regions.

READ THE FULL POSITION PAPER HERE

Social Europe

Our Mission

Team

Article Submission

Advertisements

Membership

Social Europe Archives

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Miscellaneous

RSS Feed

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641